Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Quotient Limited Soared Friday

By Jim Halley – Oct 1, 2021 at 4:55PM

Key Points

  • Quotient has only one marketed product but has another in the works.
  • The company focuses on medical diagnostic tests.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company presented good news regarding a product's potential approval in Europe.

What happened

Shares of Quotient Limited (QTNT -7.90%) rose as high as 21% on Friday. The stock hits its 52-week low on Thursday at $2.32 per share before closing at $2.34. On Friday, it opened at $2.35 before climbing to as high as $2.85 in midday training. The stock has been volatile, climbing to as high as $7.59 in the past 52 weeks, though it is still down more than 47% this year.

Scientist checking a blood sample.

Image source: Getty Images. 

So what

The blood diagnostics company announced that its MosaiQ Expanded Immunohematology (IH) blood test that tracks the levels of antigens and antibodies in the blood was beginning the review process in Europe. This is coming off successful field trials, the company said, in Europe for the IH microarray. The best news was that the company said it expects CE Mark approval by the end of the year, followed by the product's launch in the EU and other countries that accept the CE Mark, a total of roughly 40 countries, according to the company.

This isn't completely unexpected, as Quotient had said earlier this year that it planned to launch the microarray in Europe by the end of 2021. However, coming off the stock's recent two-year low, this bit of good news was able to drive its shares up considerably.

Now what

It's a huge deal for the biotech company because nearly all of its revenue right now stems from one product, its Alba by Quotient reagents. The company's 2022 fiscal year first quarter, which ended June 30, reported $9 million in revenue, up 1.3% year over year while its net loss was $24.3 million, compared to $25.4 in the same period in 2021.

New Quotient CEO Manuel O. Méndez has said that the company's MosaiQ testing platform will be its big revenue driver. If the company's MosaiQ expanded IH microarray is approved in Europe, the next step will be to seek approval in the U.S. as early as the third quarter of 2022.

The company sees other applications for the test beyond detecting antibody and antigen levels, including molecular disease screening and serological disease screening.

Jim Halley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quotient Stock Quote
$0.80 (-7.90%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.